Based on the promising efficacy obtained with niraparib and pembrolizumab in patients with platinum-resistant or secondary refractory ovarian cancer irrespective of biomarker grade [286], the phase 3 ENGOT-OV44/FIRST trial (NCT03602859) is comparing the PFS of patients with FIGO stage 3/4, non-mucinous, epithelial ovarian cancer treated with standard therapy (paclitaxel and carboplatin ± the anti-VEGF-A mAb bevacizumab, SOC) or with SOC plus the anti PD-1 mAb dostarlimab and niraparib. Here, VEGFA is linked to ovarian carcinoma.